Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Gastrointestinal disease

Pancreatitis

Calcium release-activated calcium channel (CRAC)

Cell culture studies suggest antagonizing CRAC could help treat acute pancreatitis. In a pancreatic acinar cell model of acute pancreatitis, a discontinued small molecule CRAC inhibitor research reagent from GlaxoSmithKline plc prevented excess calcium influx and necrosis. Next steps include genetic and pharmacological studies in mice to validate CRAC inhibition in a model of alcohol-induced pancreatitis.
Synta Pharmaceuticals Corp. and CalciMedica Inc. each have CRAC inhibitors in preclinical development for psoriasis, rheumatoid arthritis (RA), inflammatory bowel disease and other autoimmune and inflammatory indications.

SciBX 6(31); doi:10.1038/scibx.2013.828
Published online Aug. 15, 2013

Not patented; licensing status not applicable

Gerasimenko, J.V. et al. Proc. Natl. Acad. Sci. USA; published online
July 22, 2013;
doi:10.1073/pnas.1300910110
Contact: Ole H. Petersen, Cardiff University, Cardiff, U.K.
e-mail:

petersenoh@cardiff.ac.uk
Contact: Oleg V. Gerasimenko, same affiliation as above
e-mail:

gerasimenkoov@cardiff.ac.uk
Contact: Pawel E. Ferdek, same affiliation as above
e-mail:

ferdekpe@cardiff.ac.uk